Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

18/03/2025 Eastern Time in USA The Dow Jones Industrial Average dropped by 0.62%, closing at 41581.31 points; the Nasdaq Composite dropped by 1.71%, closing at 17504.12 points; the S&P 500 Index dropped by 1.07%, closing at 5614.66 points. Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

ADiTx Therapeutics: Overnight gain 71.6%, Funding applications, transplant technology potential, and perceived undervaluation drive stock surge amid biotech sector optimism.

Aditxt, Inc. (NASDAQ: ADTX), a Delaware-based biotechnology firm founded in 2017, is pioneering innovative solutions in the preclinical research domain. The company holds exclusive global rights to the Apoptotic DNA Immunotherapy (ADi) platform, a groundbreaking technology that mimics the body's natural mechanism for inducing tolerance to its own tissues. Focused on revolutionizing transplant medicine, Aditxt is developing a pipeline of ADi products targeting organ transplantation, skin grafting, and wound healing. The company's initial strategic emphasis lies in advancing applications for skin transplantation and other solid organ allografts. Aditxt's mission is to address critical unmet needs in transplantation medicine, with the ultimate goal of extending the lifespan and enhancing the quality of life for transplant recipients. By leveraging its proprietary ADi technology, the company aims to overcome current limitations in transplant rejection and potentially reduce the need for lifelong immunosuppression. As Aditxt progresses through its preclinical stage, investors and industry observers are closely monitoring the company's advancements in this promising field of immunotherapy and regenerative medicine.

ADiTx Therapeutics (ADTX) has experienced a notable surge in stock price, driven by multiple factors. The company's announcement of submitting four new federal funding opportunity applications signals a proactive approach to securing financial support for research and development initiatives or business expansion. As a preclinical-stage life sciences company focused on extending the lives of transplant patients, ADiTx's innovative technology in areas such as organ transplantation has attracted investor attention. Despite an 84.2% year-to-date decline, the recent 71.6% rally suggests investors perceive the stock as undervalued and are engaging in value recovery. The overall performance of the biotechnology sector has also positively influenced ADTX's stock price. This multifaceted approach to growth and the company's potential in critical medical fields have contributed to renewed investor interest in ADiTx Therapeutics (ADTX).

Regencell Bioscience Holdings Ltd.: Overnight gain 70.8%, Innovative TCM approach for neurological disorders drives investor optimism and stock surge

Regencell Bioscience Holdings Ltd., incorporated in the Cayman Islands in 2014, is a holding entity focused on the research, development, and commercialization of Traditional Chinese Medicine (TCM) for neurocognitive disorders and degenerative diseases. The company's primary emphasis is on Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). The firm is committed to enhancing the quality of life for individuals affected by ADHD and ASD, as well as their families and caregivers. Regencell Bioscience aims to establish itself as a global market leader in the treatment of ADHD and ASD through its innovative TCM-based approaches. With its strategic focus on these prevalent neurodevelopmental disorders, Regencell Bioscience is positioning itself at the intersection of traditional medicine and modern biotechnology, potentially tapping into a significant market opportunity in the rapidly evolving field of neurological treatments.

Regencell Bioscience Holdings Ltd. (RGC) has experienced a significant stock price surge due to multiple factors. The company's focus on developing Traditional Chinese Medicine (TCM) treatments for ADHD and ASD has garnered widespread industry attention. With the vast potential in the neurocognitive and degenerative disease treatment market, RGC is well-positioned as an early entrant to capture substantial market share. Positive research progress and increasing global recognition of TCM-based therapies have bolstered investor confidence. Additionally, favorable national and regional policies, such as the National Healthcare Security Administration's separate pricing for brain-computer interface technologies, have created a conducive environment for industry growth. These factors collectively contributed to RGC's 70.8% stock price increase in the latest trading session, with a year-to-date gain of 539.7%, reflecting market optimism about the company's prospects.

Blue Hat Interactive Entertainment Technology: Overnight gain 34.8%, AR Gaming Focus and Product Diversification Drive Market Optimism

Blue Hat Interactive Entertainment Technology (NASDAQ: BHAT), established in June 2018, has emerged as a leading manufacturer, developer, and operator of augmented reality (AR) interactive entertainment games and toys in China. The company specializes in developing innovative toys and interactive educational content that incorporate AR technology and mobile gaming functionality, providing immersive entertainment and learning experiences for children and adolescents. Blue Hat has successfully launched several AR products, including AR Racer and AR Crazy Bug, demonstrating its commitment to innovation in the AR space. The company places a strong emphasis on research and development team building and intellectual property protection, maintaining a leading position in AR technology, game development, and educational content creation within the industry. With a portfolio of core technology patents, Blue Hat continues to strengthen its competitive edge in the rapidly evolving AR and interactive entertainment market. The company's focus on cutting-edge AR solutions positions it well for future growth opportunities in the expanding educational technology and interactive entertainment sectors.

Blue Hat Interactive Entertainment Technology (BHAT) experienced a notable surge in stock price, driven by multiple factors. As a company specializing in augmented reality (AR) interactive entertainment games and toys, BHAT holds a strategic advantage in the current tech-focused market. The firm's diversified product portfolio, including AR Racing and AR Bugs, is viewed favorably by investors as a source of growth potential. Moreover, BHAT's numerous AR-related technology patents are considered a core competitive strength. Despite a 75.2% year-to-date decline, the recent 34.8% overnight gain suggests investors believe the stock has bottomed out, triggering a technical rebound. The overall improvement in market sentiment has also contributed to the rally in tech stocks, including BHAT. This upward movement reflects renewed investor confidence in the company's long-term prospects within the AR sector.

The Top 10 Daily Gainers in the USA market are listed as follows:

Editor's note: This content was generated by Sahm's in-house AI-enabled SaaS tool and was reviewed by our editing team.